Form 4: Cryoport Director Acquires Shares, Options Granted

Cryoport, Inc. Director Linda Baddour acquired 10,350 shares of common stock and was granted options for 16,077 shares.

Summary

• Linda Baddour, a Director at Cryoport, Inc., acquired 10,350 shares of common stock on June 5, 2026, with no cost indicated.
• Following this acquisition, Baddour beneficially owns 68,099 shares of common stock.
• Additionally, Baddour was granted options to purchase 16,077 shares of common stock at an exercise price of $15.70 per share, with an expiration date of June 5, 2033.
• These options vest incrementally, with 1/12th vesting monthly starting July 5, 2026, over a twelve-month period.
• The filing also notes a grant of restricted stock rights that vest fully on June 5, 2027, and will convert to common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating standard compensation practices and insider confidence through share acquisition, but without immediate financial performance indicators.

Positives

• Director acquisition of shares indicates confidence in the company's future.
• Grant of stock options aligns management incentives with shareholder value.
• Vesting schedule for options and restricted stock rights promotes long-term commitment.

Negatives

• The exercise price of the options ($15.70) is significantly higher than the current market price, suggesting potential for dilution if not exercised.
• The acquisition of shares was made at $0 cost, indicating these were likely part of a compensation package rather than an open market purchase.

Risks

• The value of the granted options is subject to market fluctuations and the company's stock performance.
• If the stock price does not exceed the exercise price of $15.70, the options may expire worthless.

Future Outlook

The future outlook for Cryoport, Inc. is implicitly tied to the performance of its stock, which will determine the value and exercise of the granted options and the vesting of restricted stock rights.

Management Comments

• Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
• 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.

Industry Context

StockSavvy.ai notes that insider transactions, particularly grants of options and restricted stock, are common in the biotechnology and logistics sectors as companies use equity-based compensation to attract and retain talent and align incentives with long-term growth.

Stakeholder Impact

• Shareholders: The acquisition by a director may be seen as a positive signal of confidence. The option grants could lead to future dilution if exercised, but also align management with long-term stock performance.
• Employees: The option and restricted stock grants are part of compensation, incentivizing performance and retention.
• Management: Linda Baddour benefits directly from the equity awards, with potential for significant financial gain if the stock price increases.

Next Steps

• Monitoring the vesting of restricted stock rights on June 5, 2027.
• Tracking the monthly vesting of stock options starting July 5, 2026.
• Observing the company's stock performance relative to the $15.70 option exercise price.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Stock Options, Restricted Stock, Beneficial Ownership, Cryoport Inc., CYRX, Director Transactions, Equity Awards